Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?

Markiewicz-Gospodarek, Agnieszka; Kuszta, Piotr; Baj, Jacek; Dobrowolska, Beata; Maciejewski, Ryszard

doi:10.3389/fpubh.2022.872430

Cited by 4 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study exposed the diagnostic, prognostic, and therapeutic potential of NPS screening in patients with schizophrenia, especially in relation to the E/H domain. Generally, E/H symptoms reduction can be associated with the core impact of rehabilitation, which is anxiety reduction, which is related to the overall research on NPS [ 6 , 45 , 46 ]. The results were so specific and selective, repeated across various PANSS models, that NPS may be understood as the marker of excitement/Hostility symptomatology.…”

Section: Discussionmentioning

confidence: 99%

“…The effect of neuropeptides is slow, but also much stronger, resulting in an apparent change in the modulation of the regulatory mechanism of metabolic pathways and gene expression. Markiewicz et al described the pharmacokinetic mechanism in detail in a previous publication [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

“…The assumption that cognitive functions improve along with a decrease in the level of NPS was the main objective of this study. Many publications and literature items emphasize the negative impact of stress on cognitive processes and, thus, on social cognition [ 6 ]. This approach is supported by the fact that neuropeptides perform functions analogous to those performed by neurotransmitters, neuromodulators, and neurohormones [ 31 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia

Markiewicz-Gospodarek

Dobrowolska

Maciejewski

et al. 2022

Brain Sciences

Self Cite

View full text Add to dashboard Cite

Neuropeptide S (NPS) is a factor associated with the central regulation of body weight, stress, anxiety, learning, memory consolidation, wakefulness–sleep cycle, and anti-inflammatory and neuroplastic effects. Its stress-reducing, anti-anxiety, arousal without anxiety, and pro-cognitive effects represent an interesting option for the treatment of neuropsychiatric disorders. The purpose of the study was to examine the potential associations of NPS levels in the blood with clinical and metabolic parameters during the rehabilitation therapy of patients with schizophrenia. Thirty-three male subjects diagnosed with schizophrenia were randomly divided into two groups. The rehabilitation group (REH, N16) consisted of patients who were subjected to structured, 3-month intensive rehabilitation therapy, and the control group (CON, N17) consisted of patients who were subjected to a standard support mechanism. Both groups continued their pharmacological treatment as usual. The NPS concentration, as well as clinical and metabolic parameters, were compared in both groups. Additionally, a group of healthy (H) males (N15) was tested for NPS reference scores. To look for the specificity and selectivity of the NPS relationship with clinical results, various factor models of the positive and negative syndrome scale (PANSS) were analyzed, including the original PANSS 2/3 model, its modified four-factor version, the male-specific four-factor model, and two five-factorial models validated in large groups in clinical and multi-ethnic studies. Results and conclusions: (1) Structured rehabilitation therapy, compared to unstructured supportive therapy, significantly reduced the level of schizophrenia disorders defined by various factor models derived from PANSS. (2) The clinical improvement within the 3-month rehabilitation therapy course was correlated with a significant decrease in neuropeptide S (NPS) serum level. (3) The excitement/Hostility (E/H) factor, which included schizophrenic symptoms of the psychotic disorganization, was specific and selective for the reduction in serum NPS, which was stable across all analyzed factor models. (4) The long-term relationship between serum NPS and clinical factors was not accompanied by basic metabolic parameters.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia

Markiewicz-Gospodarek

Dobrowolska

Maciejewski

et al. 2022

Brain Sciences

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neuropeptide S (NPS) has multiple neuropsychiatric functions [7], and it has been postulated that it may play an important role in regulating cognitive functioning [8]. The problem is that so far, the studies have been conducted almost exclusively on animals [9].…”

Section: Introductionmentioning

confidence: 99%

“…There are only preliminary data on the relationship between the NPS/NPSR1 system and the course of schizophrenia [7]. A case-control comparison revealed that the low func-tioning NPSR1 Asn107 variant was significantly associated with schizophrenia [27].…”

Section: Introductionmentioning

confidence: 99%

Relationship of Neuropeptide S (NPS) with Neurocognitive, Clinical, and Electrophysiological Parameters of Patients during Structured Rehabilitation Therapy for Schizophrenia

Markiewicz-Gospodarek

Maciejewski

Dobrowolska

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Introduction: Neuropeptide S is a biomarker related to various neuropsychiatric and neurocognitive functions. Since the need to improve cognitive functions in schizophrenia is unquestionable, it was valuable to investigate the possible relationships of plasma levels of NPS with neurocognitive, psychopathological and EEG parameters in patients with schizophrenia. Aim: Relationships between the serum NPS level and neurocognitive, clinical, and electrophysiological parameters were investigated in patients diagnosed with schizophrenia who underwent structured rehabilitation therapy. Methods: Thirty-three men diagnosed with schizophrenia were randomized into two groups. The REH group (N16) consisted of patients who underwent structured rehabilitation therapy, the CON group (N17) continued its previous treatment. Additionally, the reference NPS serum results were checked in a group of healthy people (N15). In the study several tests assessing various neurocognitive functions were used: d2 Sustained-Attention Test (d2), Color Trails Test (CTT), Beck Cognitive Insight Scale (BCIS), Acceptance of Illness Scale (AIS), and General Self-Efficacy Scale (GSES). The clinical parameters were measured with Positive and Negative Syndrome Scale (PANSS) and electrophysiological parameters were analyzed with auditory evoked potentials (AEPs) and quantitative electroencephalography (QEEG). The NPS, neurocognitive, clinical, and electrophysiological results of REH and CON groups were recorded at the beginning (T1) and after a period of 3 months (T2). Results: A decreased level of NPS was associated with the improvement in specific complex indices of d2 and BCIS neurocognitive tests, as well as the improvement in the clinical state (PANSS). No correlation was observed between the level of NPS and the results of AEPs and QEEG measurements. Conclusions: A decreased level of NPS is possibly related to the improvement in metacognition and social cognition domains, as well as to clinical improvement during the rehabilitation therapy of patients with schizophrenia.

show abstract

Social isolation from early life induces anxiety-like behaviors in adult rats: Relation to neuroendocrine and neurochemical dysfunctions

Dimonte¹,

Sikora²,

Bové³

et al. 2023

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Can Neuropeptide S Be an Indicator for Assessing Anxiety in Psychiatric Disorders?

Cited by 4 publications

References 78 publications

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia

Relationship of Neuropeptide S with Clinical and Metabolic Parameters of Patients during Rehabilitation Therapy for Schizophrenia

Relationship of Neuropeptide S (NPS) with Neurocognitive, Clinical, and Electrophysiological Parameters of Patients during Structured Rehabilitation Therapy for Schizophrenia

Social isolation from early life induces anxiety-like behaviors in adult rats: Relation to neuroendocrine and neurochemical dysfunctions

Contact Info

Product

Resources

About